HCM
AIMT

Highbridge Capital Management’s Aimmune Therapeutics AIMT Stock Holding History

Highbridge Capital Management’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-17,394
Closed -$261K – 1721
2016
Q3 		$261K Sell
17,394
-3,877
-18% -$52.3K ﹤0.01% 1070
2016
Q2 		$230K Buy
21,271
+7,476
+54% +$102K ﹤0.01% 1184
2016
Q1 		$188K Buy
+13,795
New +$215K ﹤0.01% 1356

Other funds holding AIMT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
TG
TLP Group Evanston, Illinois $6.61M AUM 12.46% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Highbridge Capital Management's AIMT Position: Q4 2016 in Review

Highbridge Capital Management sold out of Aimmune Therapeutics (AIMT) in Q4 2016, closing a stake of 17,394 shares — an estimated $261K sold.

Highbridge Capital Management first reported a position in AIMT in Q1 2016 and held it in 3 quarters. The position peaked at $261K in Q3 2016. 92 funds tracked by Wall St. Rank hold AIMT as of Q4 2016.

  • Highbridge Capital Management reported no remaining Aimmune Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Highbridge Capital Management sold 17,394 Aimmune Therapeutics shares in Q4 2016, an estimated $261K.
  • Highbridge Capital Management first reported a position in Aimmune Therapeutics in Q1 2016 and held it in 3 quarters.
  • Highbridge Capital Management's Aimmune Therapeutics position peaked at $261K in Q3 2016.
  • 92 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2016.

Based on Highbridge Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.